Grail's Slump Enters Week: Navigating Biotech's Setback
Grail's stock has slid as its Galleri MCED test faced a major trial setback. This piece breaks down what happened, wh...
Choosing the right guide to retirement planning is crucial for your future. Learn essential steps to secure a comfortable retirement.
22,974 articlesGrail's stock has slid as its Galleri MCED test faced a major trial setback. This piece breaks down what happened, wh...
In a choppy 2026 market, Cathie Wood isn’t chasing high-flying tech alone. She’s quietly adding to positions in three...
As markets swing, a dominant growth stock may pull back while fundamentals stay strong. This guide explains how to sp...
Lenders push automation and AI in a bid to speed closings, but costs rise and internal handoffs persist. Analysts wei...
As storms approach, cellphone carriers prepare hurricane-season readiness by leaning on AI forecasts, drone inspectio...
Investors are weighing a megadeal gamble as SpaceX mulls a public listing. Analysts warn that the moonshot rhetoric m...
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
When veterans return with their first original album in years, the headlines focus on the music. What truly stands ou...
SailPoint faced a sharp pullback after its latest results, sparking questions about growth and profitability. This ar...
A high-profile inmate known as the Gilgo Beach serial killer is spending years in isolation, reading crime fiction, a...
A Michigan case alleges a dentist billed Medicaid for work not performed. This article explains what happened, how Me...
Rising sales of probiotics and prebiotics are redefining everyday wellness budgets, while investors watch health and ...